Till startsida
To content Read more about how we use cookies on gu.se

Biomarkers in MS that reflect pathological processes, disease activity and therapeutical intervention

Principal Investigator: Jan Lycke

In several epidemiological studies, we have mapped the prevalence of MS in Sweden and among immigrant groups. We have identified risk factors for more severe forms of MS and found evidence that immune-modulating therapy leads to a favorable disease course. Clinical, neuroimaging, immunological and biochemical factors have been identified which reflect inflammatory disease activity and degenerative processes. Current projects focus on finding biomarkers in blood and spinal fluid that could guide the choice of MS therapy. We participate in several studies to develop new and more effective MS drugs. Over the last few years, interest has been directed to finding drugs that inhibit the growing disability in progressive MS, a course of MS that still lack disease modifying treatment.

Group members

Clas Malmeström, PhD, consultant in neurology and immunology

Markus Axelsson, PhD, consultant in neurology

Lenka Novakova Nyrén, PhD, consultant in neurology

Ólöf Eliasdóttir, doctoral student, consultant in neurology

Sofia Sandgren, consultant in neurology

Igal Rotenstein, resident in neurology

Ellen Lillvall, resident in neurology

Anne Brandt, research nurse

Stephani Unger, research nurse

Cecilie Scheiene, research nurse

Lena Silberberg, coordinator of the Swedish neuro-register



Page Manager: Katinka Almrén|Last update: 1/17/2019

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?